Development of a prodrug of salicylic acid, salicylic acid-L-alanine conjugate, utilizing hydrolysis by rabbit intestinal microorganisms.
The hydrolysis of salicylic acid-L-alanine conjugate (salicyl-L-alanine) following oral, intravenous, intracaecal and rectal administration (60, 10, 5 and 5 mg kg-1, respectively: salicylic acid equivalent) was examined in rabbits. Salicylic acid was detected in the blood 2 h after oral administration of salicyl-L-alanine and reached a maximum concentration at 10 h, whereas salicyl-L-alanine was rapidly eliminated. In contrast, unchanged salicyl-L-alanine only was found following intravenous administration of salicyl-L-alanine, suggesting that presystemic de-conjugation of salicyl-L-alanine was involved. The intestinal mucosal de-conjugation of salicyl-L-alanine was not recognized in the in-situ intestinal sac preparation with complete mesenteric venous blood collection. Immediate and very extensive salicylic acid formation in the caecum was found following intracaecal administration of salicyl-L-alanine. After oral pretreatment of rabbits with kanamycin sulphate, a significant inhibition of salicylic acid formation following intracaecal administration of salicyl-L-alanine was observed, indicating that the intestinal microorganisms were responsible for the biotransformation of salicyl-L-alanine. In-vitro incubation of salicyl-L-alanine with gut contents showed that the major source of its hydrolysis was the hind gut. Consequently, the blood concentration of salicylic acid was prolonged extensively following rectal administration of salicyl-L-alanine, suggesting the usefulness of salicyl-L-alanine as a prodrug of salicylic acid.
School of Pharmaceutical Sciences, Nagasaki University, Japan.
J
J
Nakamura
C
C
Tagami
K
K
Nishida
H
H
Sasaki
D000284:Administration, Oral; D000285:Administration, Rectal; D000409:Alanine / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D000818:Animals; D001711:Biotransformation; D006868:Hydrolysis; D007275:Injections, Intravenous; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000382:microbiology; D007441:Intubation, Gastrointestinal; D007612:Kanamycin / Q000494:pharmacology; D008297:Male; D011355:Prodrugs / Q000138:chemical synthesis / Q000737:chemistry*; D011817:Rabbits; D012459:Salicylates / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D020156:Salicylic Acid
D011355:Prodrugs; D012459:Salicylates; C075130:salicylic acid-alanine conjugate; D007612:Kanamycin; D020156:Salicylic Acid; D000409:Alanine